Table 3 Studies of ATRA ATO and ATO as a... | American Society of Hematology

Table 3

Studies of ATRA + ATO and ATO as a single agent in newly diagnosed APL

Therapy/study	N	CR %	Postremission PCR⁻%	Therapy	EFS %	OS %
ATO + ATRA
Hu⁶¹	85	94.1	NR	ATRA + ATO	89.2 at 5 y*	91 at 5 y
Ravandi⁶²	82	90†	100	ATRA + ATO	80 at 2 y‡	85 at 2 y
Dai⁶⁵	90	93.3		ATRA + ATO	92.2 at 3 y
ATO as a single agent
Ghavamzadeh⁶⁴	111§	85.6	92	ATO × 1	63.7 at 2 y	87.6 at 3 y‖
Mathews⁶³	72	86	76	ATO × 6	74.8 at 3 y	86.1 at 3 y
George⁶⁶	11	91	100	ATO	81.3 at 5 y	91 at 5 y

Therapy/study	N	CR %	Postremission PCR⁻%	Therapy	EFS %	OS %
ATO + ATRA
Hu⁶¹	85	94.1	NR	ATRA + ATO	89.2 at 5 y*	91 at 5 y
Ravandi⁶²	82	90†	100	ATRA + ATO	80 at 2 y‡	85 at 2 y
Dai⁶⁵	90	93.3		ATRA + ATO	92.2 at 3 y
ATO as a single agent
Ghavamzadeh⁶⁴	111§	85.6	92	ATO × 1	63.7 at 2 y	87.6 at 3 y‖
Mathews⁶³	72	86	76	ATO × 6	74.8 at 3 y	86.1 at 3 y
George⁶⁶	11	91	100	ATO	81.3 at 5 y	91 at 5 y

Disease-free survival.

A total of 95% in low risk, 81% in high risk.

Relapse-free survival.

A total of 94 of the 111 patients were newly diagnosed.

For patients in complete remission.